Trials / Completed
CompletedNCT05070663
A Study in Male and Female Adolescent Participants With Severe Uncontrolled Asthma Starting Treatment With Dupilumab Injection (Dupixent®)
National, Multicentre, Non-interventional, Prospective and Retrospective Study in Adolescent Patients With Severe Uncontrolled Asthma Starting Treatment With Dupilumab (Dupixent®)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 105 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
Primary objective: \- Describe the characteristics of enrolled severe asthma patients Secondary objectives: * Assess the control of asthma under dupilumab (Dupixent®) treatment until 1 year * Assess the clinical objectives of the asthma care * Assess comorbidities associated with Type 2 inflammation * Assess safety during the year of treatment
Detailed description
52 weeks
Conditions
Timeline
- Start date
- 2021-11-04
- Primary completion
- 2024-03-14
- Completion
- 2025-03-03
- First posted
- 2021-10-07
- Last updated
- 2025-04-29
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05070663. Inclusion in this directory is not an endorsement.